Prior to the advancement of comprehensive tumor profiling, successful implementation of a precision oncology approach included tyrosine kinase inhibitors (TKIs) imatinib for breakpoint cluster region-Abelson (BCR-ABL)-rearranged chronic myeloid leukemia [5] and trastuzumab for human epidermal growth factor 2 (HER2) immunohistochemistry (IHC) overexpressed or amplified breast cancer [6,7]. The gene discussed is ERBB2; the disease is breast carcinoma.